InvestorsHub Logo
Post# of 4972158
Next 10
Followers 61
Posts 6982
Boards Moderated 0
Alias Born 10/03/2004

Re: None

Wednesday, 07/13/2022 8:20:08 PM

Wednesday, July 13, 2022 8:20:08 PM

Post# of 4972158
Someone tell me why this stock (IPIX) is basically sitting stagnant with all its possibilities on the shelf? I know it has bad management, according to posters, but I see worse biotech stocks, with less on the shelf, outperforming IPIX by leaps & bounds.

"In the need of reinforcing the drug repositioning strategy
and developing specific SARS-CoV-2 treatment, recently,
three main groups of scientists discovered that a new
antibacterial drug, named brilacidin, provides attractive
benefits against SARS-CoV-2, and specifically without
major side effects.
This previous findings were confirmed by Xu, et al. [2],
who further, specified that the protective effect of brilacidin
is more likely to be preventive than curative, as brilacidin
has no inhibition/protective effect after SARS-CoV-2-cell
attachment, but only can inhibit SARS-CoV-2 entry into
cells.
Furthermore, while Xu, et al. [2] demonstrated the
effectiveness of brilacidin against SARS-CoV-2 and its
derivative variants including P.1 and B.1.1.7 strains, Hu, et
al. [3] discovered that brilacidin protective activity has a
broader spectrum to other sarbecoviruses, including OC43,
229E, and NL63 strains.
Highlights
1. Brilacidin protects cells from SARS-Co-2 infection,
at low dose.
2. Brilacidin has a broad-spectrum antiviral activity
against multiple Human Coronaviruses (HCoVs)
including SARS-CoV-2 and its derivatives, HCoV-
229E, HCoV-OC43, and HCoV-NL63.
3. Brilacidin has a dual antiviral mechanism of
action, including virucidal activity and binding to
coronavirus attachment factor HSPGs on the host
cell surface
https://www.jelsciences.com/articles/jbres1504.pdf

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.